This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Top-Ranked Insurance Stocks to Buy for 2018
by Zacks Equity Research
As we ring New Year, here's a list of five Top-Ranked Insurance Stocks for 2018 to make investment portfolio a compelling one for maximizing returns.
Top Ranked Growth Stocks to Buy for December 28th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 28th:
Here's Why You Should Hold Onto Cboe Global Markets Stock
by Zacks Equity Research
Cboe Global Markets (CBOE) remains well poised for growth on the back of its strong market position and a global reach with potent proprietary products.
UnitedHealth (UNH) Arm to Buy Chilean Company for $2.8B
by Zacks Equity Research
UnitedHealth (UNH) is set to buy Empresas Banmedica in order to expand its international operations.
Old Republic Issues Q4 Estimates, Okays Special Dividend
by Zacks Equity Research
Old Republic (ORI) estimates net realized investment gains of $150 million as well as to incur $45 million of additional expense in Q4. The company also approves a special dividend of $1.00 per share.
Is Cigna Corporation (CI) a Good Stock for Value Investors?
by Zacks Equity Research
Let's see if Cigna Corporation (CI) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The Zacks Analyst Blog Highlights: Wal-Mart, Procter & Gamble, NVIDIA, Cigna and McKesson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wal-Mart, Procter & Gamble, NVIDIA, Cigna and McKesson
Anthem Buys HealthSun to Expand Medicare Business in Florida
by Zacks Equity Research
Anthem's (ANTM) buyout of HealthSun reflects its long-term strategy to grow in the Medicare Advantage business.
Cigna (CI) Buys Brighter to Enhance Technology Investment
by Zacks Equity Research
Cigna's (CI) buyout of Brighter reflects its consistent efforts to scale up technological innovation.
Pick 4 Solid Insurance Stocks From the Bull Market in 2017
by Zacks Equity Research
We zero in on four best insurance bets so far this year to invest in and reap benefits from.
Anthem's (ANTM) Notes Receive Rating Action From A.M Best
by Zacks Equity Research
Anthem (ANTM) receives favorable ratings from the rating agencies on the back of operational excellence and financial flexibility
Universal Health Services (UHS) Hits 52-Week Low on Dull Q3
by Zacks Equity Research
Universal Health (UHS) stock suffers on soft third-quarter results and a tepid outlook.
Cigna (CI) Q3 Earnings Beat on Higher Enrollment, Guides Up
by Zacks Equity Research
Cigna's (CI) strong third-quarter earnings were driven by broad-based growth across its business segments.
Cigna Corp.'s (CI) Q3 Earnings and Revenues Beat, Guides Up
by Zacks Equity Research
Cigna's (CI) strong third-quarter earnings were driven by broad based growth across its business segments.
Will Higher Membership, Revenues Aid Cigna (CI) Q3 Earnings?
by Zacks Equity Research
Cigna (CI) is likely to perform well in Q3 on the back of membership growth, higher contribution from its segments and disciplined capital management.
Will Increased Visits Drive Teladoc's (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) earnings will benefit from its premier consumer engagement capabilities, broad network and scalable platform, which will increase visits and clients.
Will Lower Health Care Revenues Mar Aetna (AET) Q3 Earnings?
by Zacks Equity Research
Aetna's (AET) third-quarter earnings are likely see a drain from lesser membership and low revenues in the Health Care segment, partly offset by benefits from share buyback and cost control.
UnitedHealth (UNH) Q3 Earnings Likely to Beat: Here's Why?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter earnings are expected to benefit from strong contribution from both its segments along earnings accretion from disciplined capital management.
Markel (MKL) Issues Life Sciences Coverage in Primary Market
by Zacks Equity Research
Markel's (MKL) introduction of biomedical and life sciences coverage in the US primary insurance segment supports its strategic plan to grow organically.
Why You Should Offload Travelers (TRV) From Your Portfolio
by Zacks Equity Research
Catastrophe losses and lower investment income pose a threat to Travelers' (TRV) operational performance.
W.R. Berkley's Exposure to Cat Losses Continues to Bother
by Zacks Equity Research
W.R. Berkley's (WRB) exposure to cat losses, declining gross premiums trend as well as a continued weak performance at the global reinsurance segment raise concerns.
Prudential Financial's Organic Growth Counts, High Costs Ail
by Zacks Equity Research
Prudential Financial's (PRU) sustained operational performance and a solid capital back-up make it an investment-worthy stock. However, rising expenses remain a concern.
Why the Earnings Streak Will Continue for Cigna (CI)
by Zacks Equity Research
Cigna (CI) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
4 HMOS for Gains Amid Constant Regulatory Chaos
by Zacks Equity Research
Despite the continuing chaos and insecurity storming the health care space with respect to repeal and replace of the old order, these healthcare stocks look solid bets to put money on.
Chubb (CB) and Subsidiaries' Ratings Reiterated by A.M. Best
by Zacks Equity Research
Chubb (CB) and units' rating actions received from A.M. Best might help the property and casualty insurer retain investors' faith and write more businesses in the short term.